Woman’s Inoperable Brain Tumor Shrinks In Just Five Days Thanks To Cancer Breakthrough

In March 2024, physicians at Mass General Brigham explored a new version of CAR-T therapy on three patients suffering from recurrent glioblastoma, one of the most aggressive and deadly forms of brain cancer.

Rather than following traditional treatment methods, the researchers enhanced an existing CAR-T strategy by adding targeted antibodies, designed to improve how precisely the immune system could identify and attack tumor cells.

The therapy was administered directly into the fluid surrounding the brain and spinal cord. This method allowed the engineered immune cells to interact more closely with the tumor environment.

The results surprised the medical team. In one patient, the tumor decreased by about 18.5% within only two days and later shrank by more than 60% over the following ten weeks.

Another patient experienced a similarly fast reduction in tumor size, while a third showed noticeable changes on MRI scans within just five days after treatment.

Although these outcomes are encouraging, the study involved only three individuals and remains an early-stage trial rather than a confirmed cure.

Still, for a disease historically associated with extremely limited treatment success, the findings offer an important sign of progress. The trial provides an early indication that glioblastoma, long considered nearly untreatable, might eventually have a vulnerable point that new therapies can target.